FindTrial
Sign In

tositumomab and iodine I 131 tositumomab

RADIATION10 trials

Sponsors

SWOG Cancer Research Network, University of Nebraska, Fred Hutchinson Cancer Center, GlaxoSmithKline

Conditions

Lymphoid Leukemia in RemissionLymphomaLymphoma, Non-HodgkinStage I Chronic Lymphocytic LeukemiaStage II Chronic Lymphocytic LeukemiaStage III Chronic Lymphocytic LeukemiaStage III Small Lymphocytic LymphomaStage IV Chronic Lymphocytic Leukemia

Phase 2

Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma
CompletedNCT00006695
University of NebraskaLymphoma
Start: 2000-04-01End: 2014-12-16Updated: 2023-09-01
Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
CompletedNCT00073931
Fred Hutchinson Cancer CenterLymphoma
Start: 1999-10-31End: 2014-07-31Updated: 2015-02-05
S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
CompletedNCT00003784
SWOG Cancer Research NetworkLymphoma
Start: 1999-05-31Updated: 2013-01-24
S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
CompletedNCT00107380
SWOG Cancer Research NetworkLymphoma
Start: 2005-11-30End: 2015-12-31Updated: 2016-03-07
Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission
CompletedNCT00476047
Fred Hutchinson Cancer CenterLymphoid Leukemia in Remission, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia +4
Start: 2007-02-28End: 2015-02-28Updated: 2017-10-12
Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab
CompletedNCT00933335
GlaxoSmithKlineLymphoma, Non-Hodgkin
Start: 1998-08-31End: 2010-08-31Updated: 2017-01-18
Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody
CompletedNCT00938041
GlaxoSmithKlineLymphoma, Non-Hodgkin
Start: 1998-04-30End: 2013-06-30Updated: 2017-01-09
Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma
CompletedNCT00989664
GlaxoSmithKlineLymphoma, Non-Hodgkin
Start: 1996-11-30End: 2008-09-30Updated: 2016-12-13

Phase 3

Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
TerminatedNCT00004874
University of NebraskaLymphoma
Start: 1998-11-30End: 2012-11-30Updated: 2018-01-17
Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma
CompletedNCT00268983
GlaxoSmithKlineLymphoma, Non-Hodgkin
Start: 2004-10-31End: 2013-06-30Updated: 2017-01-09